Key Drivers
- Cash Runway
- Zero Revenue
- Ongoing Dilution
AIAI Summary
TYRA is no longer a survival story thanks to its $354m cash runway through 2H 2028, but the investment now hinges almost entirely on whether SURF302 can validate the FGFR3/SNAP platform at the September 2026 readout; weak data would likely compress the stock quickly despite the balance sheet, while strong data could re-rate the story materially.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Runway
- •Zero Revenue
- •Ongoing Dilution
TYRA has a very strong cash position and minimal debt, but with no revenue, ongoing losses, continued cash burn, and dilution, the investment case depends on how long its balance-sheet runway can support development.
Price Behavior
Key Price Behavior Insights:
- •Downtrend intact
- •$25 support
- •Weak rebound
TYRA remains weak after breaking below $30–33 last month, but stabilization around $25 suggests near-term support while any rebound stays unconfirmed until $26.5–27 is reclaimed.
Sharp downside break from the low-$30s into the mid-$20s on 2026-08-04
Sentiment & News
Key News Insights:
- •SURF302 Readout
- •BEACH301 Delay
- •Strong Cash Runway
TYRA has a near-term binary catalyst in September 2026 SURF302 Phase 2 data, while BEACH301 was delayed to Q1 2027 and the company remains well funded into 2H 2028.
The upcoming SURF302 data could be a major stock mover, with positive results likely boosting confidence in TYRA's pipeline and platform
Similar Companies in Healthcare
Other companies in the same sector with AI ratings